Onsite Industry Guide | ACP IMM 2022 - 23

Now you can
detect cancer
with a simple
blood draw
1
The future of multi-cancer early detection has arrived
Fighting cancer starts
with knowing it's there.
~70% of cancer deaths
are caused by cancers
without recommended
screenings.2
Potential to detect
more cancers, early.
Using a multi-cancer early
detection test alongside existing
recommended screening can help
detect more cancers early.
Ability to detect a cancer
signal across 50+ cancer types.1
When a cancer signal
is detected, the test
can predict its origin with
high accuracy.
Important Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be
used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer
signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of " Cancer Signal Not Detected " does not rule
out cancer. A test result of " Cancer Signal Detected " requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in
a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test
results do occur. Rx only.
Laboratory/Test Information
GRAIL's clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP).
The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug
Administration. GRAIL's clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Visit us at booth #1922
1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. doi: 10.1016/j.
annonc.2021.05.806.
2. For US population ages 50-79. Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on estimated proportion of lung cancers that occur in
screen-eligible individuals older than 40 years). Source: Estimated deaths per year in 2021 from American Cancer Society Cancer Facts and Figures 2021. Available at: http://www.cancer.org/content/dam/cancer-org/
research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf. Data on file GA-2021-0065
©2022 GRAIL, LLC. ALL RIGHTS RESERVED
GALLERI IS A REGISTERED TRADEMARK OF GRAIL, LLC.
|
US-GA-2200042-1

https://www.galleri.com/hcp

Onsite Industry Guide | ACP IMM 2022

Table of Contents for the Digital Edition of Onsite Industry Guide | ACP IMM 2022